- Home
- PRME vs TERN Comparison
PRME vs TERN Comparison
Compare PRME & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- TERN
- Stock Information
- Founded
- PRME 2019
- TERN 2017
- Country
- PRME United States
- TERN United States
- Employees
- PRME N/A
- TERN N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- TERN Health Care
- Exchange
- PRME Nasdaq
- TERN Nasdaq
- Market Cap
- PRME 588.2M
- TERN 508.8M
- IPO Year
- PRME 2022
- TERN 2021
- Fundamental
- Price
- PRME $4.02
- TERN $9.69
- Analyst Decision
- PRME Strong Buy
- TERN Strong Buy
- Analyst Count
- PRME 9
- TERN 5
- Target Price
- PRME $14.75
- TERN $15.90
- AVG Volume (30 Days)
- PRME 514.1K
- TERN 3.2M
- Earning Date
- PRME 11-01-2024
- TERN 08-05-2024
- Dividend Yield
- PRME N/A
- TERN N/A
- EPS Growth
- PRME N/A
- TERN N/A
- EPS
- PRME N/A
- TERN N/A
- Revenue
- PRME $591,000.00
- TERN N/A
- Revenue This Year
- PRME N/A
- TERN N/A
- Revenue Next Year
- PRME N/A
- TERN N/A
- P/E Ratio
- PRME N/A
- TERN N/A
- Revenue Growth
- PRME N/A
- TERN N/A
- 52 Week Low
- PRME $3.47
- TERN $3.26
- 52 Week High
- PRME $12.45
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PRME 45.66
- TERN 59.43
- Support Level
- PRME $3.71
- TERN $8.56
- Resistance Level
- PRME $4.19
- TERN $11.00
- Average True Range (ATR)
- PRME 0.32
- TERN 0.91
- MACD
- PRME 0.04
- TERN 0.16
- Stochastic Oscillator
- PRME 51.40
- TERN 61.31
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.